Fruquin 5 mg (Fruquintinib) Capsles

FRUQUIN (Fruquintinib INN) 5 mg Capsule is an oral targeted anticancer medicine indicated for the treatment of metastatic colorectal cancer (mCRC) in adults who have previously received standard treatment therapies. It belongs to a class of medicines known as vascular endothelial growth factor receptor (VEGFR) inhibitors, which help slow the progression of cancer by reducing the formation of new blood vessels that tumors need for growth and spread.

Therapeutic Uses

• Treatment of previously treated metastatic colorectal cancer (mCRC)
• Helps delay tumor progression in eligible patients
• Inhibits tumor angiogenesis by targeting VEGFR pathways
• Used as a targeted therapy under the supervision of an oncology specialist
• May contribute to improved progression-free survival in selected patients
• Intended for patients whose disease has progressed after conventional chemotherapy and other recommended treatment options

Therapeutic Effects

• Slows the growth and spread of cancer cells
• Reduces blood vessel formation that nourishes tumors
• Supports disease control in advanced colorectal cancer
• Provides targeted inhibition of cancer-related angiogenesis
• Helps improve treatment outcomes when used according to prescribed oncology protocols

Active Ingredient

• Fruquintinib INN – 5 mg per capsule

Composition
Each hard capsule contains Fruquintinib 5 mg (INN) as the active pharmaceutical ingredient. Fruquintinib is a highly selective vascular endothelial growth factor receptor (VEGFR-1, VEGFR-2, and VEGFR-3) tyrosine kinase inhibitor that blocks angiogenesis, thereby reducing the blood supply required for tumor growth and metastasis.

The formulation also contains pharmaceutical-grade inactive ingredients that help maintain capsule stability, quality, and consistent drug delivery. Refer to the product packaging or prescribing information for the complete list of excipients if required.

Important: Use this medicine only under the guidance of a qualified oncology specialist.

Recommended Adult Dose

• The usual recommended dose is 5 mg orally once daily.
• Treatment is generally given for 21 consecutive days, followed by 7 days without treatment, completing a 28-day treatment cycle.
• Continue therapy for as long as clinical benefit is observed or until unacceptable toxicity occurs, as determined by the treating physician.

Administration Instructions

• Swallow the capsule whole with water.
• Do not crush, chew, or open the capsule.
• The medicine may be taken with or without food.
• Take it at approximately the same time each day to maintain consistent drug levels.

Missed Dose

• If a dose is missed, do not take an extra capsule to make up for it.
• Skip the missed dose and take the next scheduled dose at the regular time.

Additional Guidance

• Regular monitoring of blood pressure, liver function, kidney function, and treatment-related adverse effects may be required during therapy.
• Dose interruption, reduction, or discontinuation may be necessary if significant side effects occur, following the advice of the treating oncologist.
• Do not change the prescribed dose or stop treatment without consulting your healthcare provider.

Note: Dosage should always follow the latest prescribing information and the recommendation of the treating oncologist.